Evidence supporting the use of: Bifidobacterium breve
For the health condition: Allergies (respiratory)

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Bifidobacterium breve has been investigated in scientific studies for its potential to modulate immune responses and support the management of respiratory allergies, such as allergic rhinitis and asthma. Several clinical trials and animal studies have assessed its effects on allergic inflammation and immune balance. The proposed mechanism involves the ability of B. breve to promote regulatory T-cell activity, enhance the gut barrier, and reduce pro-inflammatory cytokine production, thereby supporting a healthier immune response to environmental allergens.

Some human studies, particularly in children, have found that supplementation with B. breve (alone or in combination with other probiotic strains) can reduce the frequency and severity of respiratory allergic symptoms, including wheezing and rhinitis. For example, a few randomized controlled trials (RCTs) reported improvements in symptoms and decreased use of rescue medications in children with allergic rhinitis or asthma. However, results are not consistent across all studies, and some have found no significant benefit. The overall quality of evidence is moderate, with small sample sizes and varied probiotic formulations limiting firm conclusions.

In summary, there is preliminary scientific evidence suggesting a potential benefit of Bifidobacterium breve for supporting respiratory allergy management, but this evidence is not robust. Larger, well-designed clinical trials are needed to confirm efficacy and clarify optimal usage. Therefore, the evidence rating is set at 2 out of 5, reflecting early but inconclusive scientific support.

More about Bifidobacterium breve
More about Allergies (respiratory)